Macular degeneration: trials for referral
261 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
261 trials shown
Phase 366 sites
RecruitingAustria, Switzerland, Czechia, Germany, Denmark, Spain
NCT06847542
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
Hoffmann-La Roche
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 3243 sites
RecruitingAustria, Australia, Canada, Germany, Spain, France
NCT06541704
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 20 sites
Not yet recruiting
NCT07798375
A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration
Everest Medicines (China) Co.,Ltd.
Pre-treatment window Registry sentence: “Treatment-naïve CNV secondary to AMD (nAMD)”
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 1/22 sites
RecruitingUnited States
NCT04339764
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
National Eye Institute (NEI)
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govNo phase0 sites
Not yet recruiting
NCT07915076
Safety and Clinical Performance of the LENTIS® MAX LS-313 MF80 Compared With the Monofocal L-313 in Cataract Patients With Late Age-Related Macular Degeneration: A Multicenter Comparative Clinical Investigation.
Teleon Surgical B.V.
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 22 sites
RecruitingUnited States
NCT07557121
Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration
AiViva BioPharma, Inc.
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govNo phase3 sites
Not yet recruitingCanada
NCT07917715
MacuMira Microcurrent Stimulation for Dark Adaptation in Dry Age-Related Macular Degeneration
Clarity Eye Institute
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingChina
NCT06737354
Safety and Efficacy Study of IVB103 Injection in Subjects With Neovascular (Wet) Agerelated Macular Degeneration (nAMD).
InnoVec Biotherapeutics Inc.
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 2/3105 sites
RecruitingAustralia, Belgium, Canada, Switzerland, China, Czechia
NCT06635148
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Janssen Research & Development, LLC
Registry updated 3 Nov 2026 · The registries disagree on the status
Registry record: ClinicalTrials.govPhase 13 sites
RecruitingUnited States
NCT07594236
Phase 1 Study of C.001 in Retinal Degeneration
Cellio Therapeutics Inc
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 3145 sites
RecruitingAustria, Belgium, Bulgaria, Canada, Czechia, Germany
NCT07007065
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
AbbVie
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 1/21 site
RecruitingChina
NCT07185841
Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD)
Fujian Haixi Pharmaceuticals Co., Ltd.
Pre-treatment window Registry sentence: “Treatment-naive , or previous anti-VEGF treatment that was effective and discontinued for more than 3 months, with OCT evidence of subretinal fluid or cystoid macular edema;”
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 3164 sites
RecruitingArgentina, Austria, Australia, Belgium, Brazil, Switzerland
NCT03683251
Extension Study for the Port Delivery System With Ranibizumab (Portal)
Hoffmann-La Roche
Registry updated 27 Oct 2026 · The registries disagree on the status
Registry record: ClinicalTrials.govNo phase1 site
By invitation onlyUnited States
NCT07747662
Adaptive Optics Scanning Light Ophthalmoscopy (AOSLO) and Microperimetry (MP) Sub-study
University of Wisconsin, Madison
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.govPhase 25 sites
RecruitingUnited States
NCT07851259
A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Genentech, Inc.
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.govPhase 41 site
Not yet recruitingUnited States
NCT07891910
Iopidine to Decrease Intraocular Pressure Rise After Injections
Retina Consultants of Delmarva
Registry updated 23 Oct 2026
Registry record: ClinicalTrials.govPhase 225 sites
RecruitingArmenia, Germany, France, Georgia, Ireland, Israel
NCT06659549
A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
Galimedix Therapeutics Inc
Registry updated 22 Oct 2026
Registry record: ClinicalTrials.govPhase 1/235 sites
RecruitingAustralia, United Kingdom, United States
NCT07215234
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Sanofi
Registry updated 20 Oct 2026
Registry record: ClinicalTrials.govPhase 255 sites
RecruitingUnited States
NCT07205887
A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO
EyeBiotech Ltd.
Pre-treatment window Registry sentence: “Have treatment naive subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) or juxtafoveal/extrafoveal CNV with foveal involvement”
Registry updated 20 Oct 2026
Registry record: ClinicalTrials.govPhase 3126 sites
RecruitingArgentina, Australia, Bulgaria, Germany, Spain, France
NCT07064759
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
4D Molecular Therapeutics
Pre-treatment window Registry sentence: “Treatment naïve, i.e. no prior IVT anti-VEGF therapy OR”
Registry updated 19 Oct 2026
Registry record: ClinicalTrials.govPhase 1/21 site
RecruitingChina
NCT07418177
Study in Human iPSCs-derived RPE Cells Transplantation for Advanced (Late-stage) AMD
The First Affiliated Hospital with Nanjing Medical University
Registry updated 19 Oct 2026
Registry record: ClinicalTrials.govPhase 1/28 sites
RecruitingUnited Kingdom, United States
NCT07392255
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)
Complement Therapeutics
Registry updated 16 Oct 2026
Registry record: ClinicalTrials.govPhase 12 sites
RecruitingGreece, United States
NCT05147701
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Exosomes for NAION
The Foundation for Orthopaedics and Regenerative Medicine
Registry updated 16 Oct 2026
Registry record: ClinicalTrials.govPhase 3108 sites
RecruitingCzechia, Spain, Hungary, Japan, Lithuania, Latvia
NCT07614776
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
Amgen
Pre-treatment window Registry sentence: “Active, treatment-naïve subfoveal CNV lesions secondary to nAMD including juxtafoveal lesions that affect the fovea as confirmed by SD-OCT and FA in the study eye (SE)”
Registry updated 14 Oct 2026
Registry record: ClinicalTrials.govPhase 217 sites
RecruitingIsrael, United States
NCT05626114
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251
Genentech, Inc.
Registry updated 14 Oct 2026
Registry record: ClinicalTrials.govPhase 257 sites
RecruitingArgentina, Australia, Bulgaria, Brazil, Canada, Colombia
NCT07441642
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Novartis Pharmaceuticals
Registry updated 13 Oct 2026
Registry record: ClinicalTrials.govPhase 1/27 sites
RecruitingUnited States
NCT07587515
Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration
Eyconis INC.
Registry updated 9 Oct 2026
Registry record: ClinicalTrials.govPhase 1/211 sites
RecruitingUnited States
NCT06467344
Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
Ascidian Therapeutics, Inc
Registry updated 7 Oct 2026
Registry record: ClinicalTrials.govPhase 2/3132 sites
RecruitingArgentina, Australia, Switzerland, Germany, Estonia, Spain
NCT07440225
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
EyeBiotech Ltd.
Pre-treatment window Registry sentence: “Has treatment naive choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) including subfoveal, juxtafoveal and extrafoveal lesions or retinal angiomatous proliferations (RAP) and polypoidal choroidal vascularization (PCV) lesions in at least one eye (study eye)”
Registry updated 2 Oct 2026
Registry record: ClinicalTrials.govPhase 314 sites
RecruitingRussia
NCT07844148
A Study to Compare GNR-139 and Eylea® in Patients With nAMD
AO GENERIUM
Pre-treatment window Registry sentence: “Previously untreated active MNV secondary to nAMD (i.e., presence of FFA leakage, as well as IRF and/or SRF and/or subretinal hyperreflective material and/or serous or fibrovascular RPE detachment based on OCT data) meeting the following criteria: 5.1.”
Registry updated 30 Sept 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States97 open trials
- China35 open trials
- France28 open trials
- Italy27 open trials
- Germany23 open trials
- Spain23 open trials
- United Kingdom22 open trials
- Australia18 open trials
- Austria16 open trials
- Poland13 open trials
- Czechia13 open trials
- Hungary13 open trials
- Switzerland11 open trials
- South Korea9 open trials
- Canada9 open trials
- Portugal9 open trials
- Israel9 open trials
- Greece6 open trials
- Argentina6 open trials
- Singapore6 open trials
- Latvia5 open trials
- Türkiye4 open trials
- Bulgaria4 open trials
- Japan4 open trials
- Puerto Rico4 open trials
- Hong Kong4 open trials
- Denmark3 open trials
- Slovakia3 open trials
- Brazil3 open trials
- Taiwan3 open trials
- Romania3 open trials
- New Zealand3 open trials
- Belgium2 open trials
- Netherlands2 open trials
- Croatia2 open trials
- Georgia2 open trials
- Ireland2 open trials
- Lithuania2 open trials
- Colombia2 open trials
- Estonia2 open trials
- India2 open trials
- Slovenia2 open trials
- Thailand1 open trial
- Armenia1 open trial
- Russia1 open trial
- Pakistan1 open trial
- Norway1 open trial
- United Arab Emirates1 open trial
- Costa Rica1 open trial
- Bangladesh1 open trial
- Sweden1 open trial
- Egypt1 open trial
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Intersectoral Research and Technology Complex Eye Microsurgery
Moscow, Russia
1 trial · 13 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
Closed for recruitment
Regulatory Post-Marketing Surveillance Study for Brolucizumab
NCT04985487 · No phase · South Korea
Source: ClinicalTrials.govOpened for recruitment
A Study in Adults With Geographic Atrophy
NCT07606365 · Phase 2 · Argentina, Australia, Switzerland, Czechia, United Kingdom, Poland
Source: ClinicalTrials.govOpened for recruitment
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269 · Phase 2 · Austria, Australia, Canada, Switzerland, Czechia, Germany
Source: ClinicalTrials.govStatus changed: Running, not recruiting → Completed
A Safety and Tolerability Clinical Trial of PST-611 in Dry Age-related Macular Degeneration
NCT07024732 · Phase 1 · France
Source: ClinicalTrials.govPhase changed: Phase 4 → Phase 3
NCT07007065 · Phase 3 · Austria, Belgium, Bulgaria, Canada, Czechia, Germany
Source: ClinicalTrials.govPhase changed: Phase 4 → Phase 3
Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)
NCT06952452 · Phase 3 · Spain
Source: ClinicalTrials.govOpened for recruitment
Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)
NCT06952452 · Phase 3 · Spain
Source: ClinicalTrials.govClosed for recruitment
NCT06795048 · Phase 4 · Australia, Canada, China, Germany, Spain, France
Source: ClinicalTrials.govClosed for recruitment
NCT05949593 · Phase 3 · Australia, Switzerland, China, Czechia, France, United Kingdom
Source: ClinicalTrials.govPhase changed: Phase 1/2 → Phase 2
NCT05481827 · Phase 2 · Australia, Germany, Spain, France, United Kingdom, Poland
Source: ClinicalTrials.govOpened for recruitment
NCT05481827 · Phase 2 · Australia, Germany, Spain, France, United Kingdom, Poland
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
The Sahlgrenska Anti-VEGF Study
NCT04101877 · Phase 2 · Sweden
Source: ClinicalTrials.govOpened for recruitment
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
NCT03999801 · Phase 2 · Germany, Spain, France, Hungary, Italy, United States
Source: ClinicalTrials.govOpened for recruitment
Extension Study for the Port Delivery System With Ranibizumab (Portal)
NCT03683251 · Phase 3 · Argentina, Austria, Australia, Belgium, Brazil, Switzerland
Source: ClinicalTrials.govOpened for recruitment
NCT05949593 · Phase 3 · Australia, Switzerland, China, Czechia, France, United Kingdom
Source: ClinicalTrials.govClosed for recruitment
NCT05481827 · Phase 2 · Australia, Germany, Spain, France, United Kingdom, Poland
Source: ClinicalTrials.govClosed for recruitment
Extension Study for the Port Delivery System With Ranibizumab (Portal)
NCT03683251 · Phase 3 · Argentina, Austria, Australia, Belgium, Brazil, Switzerland
Source: ClinicalTrials.govClosed for recruitment
Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)
NCT06952452 · Phase 3 · Spain
Source: ClinicalTrials.govOpened for recruitment
NCT06795048 · Phase 4 · Australia, Canada, China, Germany, Spain, France
Source: ClinicalTrials.gov
Show more
Status changed: By invitation only → Not yet recruiting
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
NCT03999801 · Phase 2 · Germany, Spain, France, Hungary, Italy, United States
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269 · Phase 2 · Austria, Australia, Canada, Switzerland, Czechia, Germany
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
A Study in Adults With Geographic Atrophy
NCT07606365 · Phase 2 · Argentina, Australia, Switzerland, Czechia, United Kingdom, Poland
Source: ClinicalTrials.govStatus changed: Running, not recruiting → Completed
NCT05698329 · Phase 1 · United States
Source: ClinicalTrials.govStatus changed: By invitation only → Recruiting
NCT06737354 · Phase 1 · China
Source: ClinicalTrials.govNew in the registry
MacuMira Microcurrent Stimulation for Dark Adaptation in Dry Age-Related Macular Degeneration
NCT07917715 · No phase · Canada
Source: ClinicalTrials.gov
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
Phase 2Ended 30 Sept 2026
Completed168 participants
NCT05230537
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
No phaseEnded 29 Sept 2026
Withdrawn before start0 participants
NCT05780931
Rehabilitating Vision Loss in Veterans With Age-Related Macular Degeneration
Reason given: I was instructed to stop the study, because the underlying VA grant has run out of funds.
Phase 2Ended 22 Sept 2026
No phaseEnded 30 Aug 2026
Completed54 participants
NCT07235527
Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration
Phase 1/2Ended 25 Aug 2026
Completed177 participants
NCT04567303
Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration
Phase 1/2Ended 11 Aug 2026
Completed38 participants
NCT06664502
A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
Phase 4Ended 11 Aug 2026
Completed50 participants
NCT07779356
Patient Comfort Following Intravitreal Injections Using Iheezo Versus Standard Anesthesia
Phase 4Ended 14 Jul 2026
Completed35 participants
NCT06683950
Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment
Phase 2Ended 1 Jul 2026
Completed170 participants
NCT06116890
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
No phaseEnded 1 Jul 2026
Completed12 participants
NCT07744984
The Efficacy of Home OCT Supported Management in Patients Diagnosed With Neovascular-AMD and Undergoing a Drug Switch to Faricimab
No phaseEnded 14 Jun 2026
Phase 2Ended 1 Jun 2026
No phaseEnded 22 May 2026
Completed10 participants
NCT07318428
AI-Assisted Detection of Posterior Segment Diseases: DR, AMD, RVO, and Glaucoma
No phaseEnded 20 May 2026
Phase 3Ended 17 May 2026
Completed70 participants
NCT06305416
A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema
Phase 1/2Ended 15 May 2026
Phase 1/2Ended 6 May 2026
Phase 2Ended 9 Apr 2026
Completed30 participants
NCT07550504
A Study to Evaluate the Usability of the SB11 PFS in Trial Participants With Wet AMD, Macular Oedema Secondary to RVO, or mCNV
Phase 1Ended 7 Apr 2026
Completed8 participants
NCT07024732
A Safety and Tolerability Clinical Trial of PST-611 in Dry Age-related Macular Degeneration
Phase 4Ended 11 Mar 2026
Completed50 participants
2024-514408-15-00
Two initial faricimab loading doses in treatment-naive neovascular AMD
Show more
Phase 1Ended 3 Mar 2026
Stopped early27 participants
NCT06961370
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Reason given: The study was terminated prematurely by the Sponsor due to observation of dose-limiting adverse events meeting the protocol-defined stopping criteria.
No phaseEnded 1 Mar 2026
Completed742 participants
NCT06890026
Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration
- Durability of Three Monthly Loading Doses with Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration. · Ophthalmology and therapy, 2026
Phase 2Ended 23 Feb 2026
Phase 2Ended 18 Feb 2026
Completed300 participants
NCT05839041
A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Phase 1Ended 16 Feb 2026
No phaseEnded 5 Feb 2026
Withdrawn before start0 participants
NCT05941273
A Study of the SING IMT in an Israeli Cohort
Reason given: This decision is driven by the sponsor's strategic considerations.
Phase 3Ended 30 Jan 2026
Withdrawn before start0 participants
NCT05126966
A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration
Reason given: Roche/Genentech has initiated an immediate pause of all new PDS implantations because the implants from commercial supply in the clinical studies did not meet the filed specifications for the intended use
No phaseEnded 31 Dec 2025
No phaseEnded 31 Dec 2025
Completed1000 participants
NCT05698316
A Collaborative Resource of Heidelberg Multimodal Imaging of Intermediate and Early Atrophic AMD Cases to Study Prediction of Disease Progression
Phase 1Ended 17 Dec 2025
Completed17 participants
NCT05953012
Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration
Phase 3Ended 12 Dec 2025
No phaseEnded 11 Dec 2025
Completed234 participants
NCT05797896
Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study
Phase 1Ended 9 Dec 2025
Completed164 participants
NCT07484074
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324
Phase 4Ended 2 Dec 2025
No phaseEnded 28 Nov 2025
Phase 1Ended 21 Nov 2025
Completed12 participants
NCT06213038
A Clinical Study Evaluating the Safety and Efficacy of SKG0106 in Patients With Neovascular Age-related Macular Degeneration (nAMD)
No phaseEnded 17 Nov 2025
Phase 1Ended 10 Nov 2025
Completed21 participants
NCT05643118
Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration
Phase 1/2Ended 3 Nov 2025
Completed56 participants
NCT05456828
A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration
Phase 4Ended 14 Oct 2025
No phaseEnded 22 Sept 2025
Completed100 participants
NCT07206654
Prevalence and Determinants of Shoulder Girdle Musculoskeletal Complaints in Geriatric Patients With Diminished Vision
No phaseEnded 15 Sept 2025
Completed290000 participants
NCT07105228
Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study
Phase 3Ended 10 Sept 2025
Phase 3Ended 5 Sept 2025
Completed792 participants
NCT04770545
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
No phaseEnded 1 Sept 2025
Completed550000 participants
NCT06769412
A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)
No phaseEnded 15 Aug 2025
Completed57 participants
NCT03225131
Dark Adaptation in Participants With Age-Related Macular Degeneration
No phaseEnded 12 Aug 2025
No phaseEnded 14 Jul 2025
Completed150 participants
NCT05667441
Adherence to Lifestyle Changes for Age-related Macular Degeneration
Phase 2Ended 1 Jul 2025
No phaseEnded 30 Jun 2025
No phaseEnded 15 Jun 2025
Completed95 participants
NCT05447650
Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration (i-SIGHT)
Phase 3Ended 31 May 2025
Withdrawn before start0 participants
NCT04697953
Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)
Reason given: Study terminated - no participants were enrolled.
No phaseEnded 27 May 2025
Completed32 participants
NCT06381596
Retinal Fundus Flavoprotein Fluorescence in Age Related Macular Degeneration
No phaseEnded 27 May 2025
Completed62 participants
NCT05961332
COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy
No phaseEnded 1 May 2025
Completed64 participants
NCT05542381
The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain
Phase 3Ended 22 Apr 2025
Completed488 participants
NCT05439629
Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration
Phase 3Ended 17 Apr 2025
Completed289 participants
2023-509206-29-00
A Clinical Trial to compare Efficacy, Safety, Tolerability of RBS-001 to Eylea® in Subjects with Neovascular Age-Related Macular Degeneration
Phase 3Ended 10 Apr 2025
Completed278 participants
NCT05536297
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
No phaseEnded 7 Apr 2025
Stopped early15 participants
NCT05200624
Subthreshold Laser Treatment in Intermediate Age-related Macular Degeneration With Nascent Geographic Atrophy Study
Reason given: Difficulty with meeting recruitment targets
Phase 3Ended 31 Mar 2025
Completed475 participants
NCT04757636
A clinical study of OPT-302 with aflibercept compared to aflibercept alone in patients with neovascular age-related macular degeneration
- Neovascular age-related macular degeneration management - Beyond anti-VEGF. · Indian journal of ophthalmology, 2026
Not medical advice. fetched 9 Nov 2026